Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain

被引：0
|
作者：
Ortega Granados, A. L. [1 ]
Rojo Todo, F. [2 ]
Alvarez Alvarez, R. [3 ]
Majem Tarruella, M. [4 ]
Ruiz de Alda Iparraguirre, L. [5 ]
Garcia Verdes-Montenegro, J. F. [6 ]
Gordo Flores, R. [6 ]
Gonzalez-Dominguez, A. [7 ]
Ivanova Markova, Y. [7 ]
Sanchez San Cristobal, R. [7 ]
机构：
[1] Complejo Hosp Jaen, Med Oncol, Jaen, Spain
[2] Hosp Univ Fdn Jimenez Diaz, Pathol Anat, Madrid, Spain
[3] Hosp Gregorio Maranon, Med Oncol, Madrid, Spain
[4] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain
[5] Roche, Corp Affairs, Madrid, Spain
[6] Roche, Dept Med, Madrid, Spain
[7] Weber, Pharmacoecon & Market Access, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1809
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1204P
引用
收藏
页码：S960 / S960
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [22] Difference in Benefit of Chemotherapy Between Small Cell Lung Cancer Patients with Interstitial Pneumonia and Patients with Non-small Cell Lung Cancer
    Kashiwabara, Kosuke
    Semba, Hiroshi
    Fujii, Shinji
    Tsumura, Shinsuke
    Aoki, Ryota
    ANTICANCER RESEARCH, 2015, 35 (02) : 1065 - 1071
  • [23] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2019, 36 : 1114 - 1125
  • [24] Trends in ALK inhibitors for non-small cell lung cancer.
    Meade, Denise
    Ng, Marie
    Alford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [26] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [27] Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK plus NSCLC).
    Berge, Eamon
    Delee, Maxon
    Lu, Xian
    Baron, Anna E.
    Solomon, Benjamin J.
    Doebele, Robert Charles
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
    Awad, Mark
    Mastini, Cristina
    Patino, Rafael
    Mologni, Luca
    Voena, Claudia
    Mussolin, Lara
    Mach, Stacy
    Adeni, Anika
    Lydon, Christine
    Janne, Pasi
    Chiarle, Roberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1163
  • [29] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [30] ALK COPY NUMBER CHANGES IN NON-SMALL CELL LUNG CANCER
    Arriola, Edurne
    Taus, Alvaro
    Salido, Marta
    Galvan, Ana B.
    Martinez-Aviles, Luz
    Gimeno, Javier
    Serrano, Sergio
    Bellosillo, Beatriz
    Sole, Francesc
    Albanell, Joan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S507 - S508
12345